Are there any side effects of pemetinib/pemetinib? What is the effect

Pemigatinib is a small molecule inhibitor targeting fibroblast growth factor receptor (FGFR) 1, 2, and 3. It is mainly used to treat patients with locally advanced or metastatic cholangiocarcinoma accompanied by FGFR2 fusion or rearrangement mutations. As the world's first targeted drug approved for the treatment of FGFR2-positive cholangiocarcinoma, pemetinib brings new hope to some patients who lack effective systemic treatment options.

In terms of therapeutic effect, pemetinib has shown a relatively ideal disease control rate in some patients withFGFR2-positive cholangiocarcinoma. Because it is a precision treatment drug, its efficacy is mainly concentrated in patients with confirmed FGFR2 mutations through molecular testing. For this group of people, pemetinib can effectively control the growth and spread of tumor cells by inhibiting the activity of the FGFR signaling pathway. In clinical applications, some patients can see tumor shrinkage or slow growth in the short term, thereby stabilizing their condition and improving their quality of life. However, it should be noted that its efficacy varies among individuals and depends on factors such as genetic background, disease course, and previous treatment history. Therefore, different patients may respond differently to drugs even if they have the same genetic mutation.

As for side effects, pemetinib is generally considered to be well tolerated, but it is not an ideal drug with “no toxic side effects.” In actual use, the more common adverse reactions include hyperphosphatemia, dry skin, hair loss, diarrhea, fatigue, decreased appetite, eye discomfort, etc. Among them, hyperphosphatemia is considered to be one of the most typical side effects of this drug. Because FGFR is involved in the regulation of phosphorus metabolism, its inhibition may lead to an increase in blood phosphorus levels. Although most side effects are mild to moderate, they require close monitoring, especially during long-term treatment, as metabolic disorders or kidney function problems may occur if left unintervened. In addition, some patients may also experience rare but serious adverse reactions, such as blurred vision or corneal lesions and other ophthalmic problems. Once such side effects occur, the drug needs to be discontinued in time and referred to an ophthalmology department for further treatment.

For the management of side effects, current clinical practice often recommends the strategy of "monitoring-intervention-adjustment", that is, regular blood phosphorus testing, giving a low-phosphorus diet, or using phosphorus-lowering drugs to control electrolyte levels. If the patient does not tolerate it well, toxicity can be reduced by intermittent administration or dose reduction. Doctors often adjust treatment plans based on patient specific responses to balance efficacy and quality of life.

It is important to note that pemetinib is only suitable for patients with specific gene mutations. If used blindly without molecular testing, it is likely to not achieve the expected efficacy and will be exposed to the risk of side effects. Therefore, before deciding whether to use pemetinib, accept evaluation from an authoritative medical institutionNGS genetic testing is a prerequisite. At the same time, the entire medication cycle should be carried out under the guidance of professional oncologists, and any side effects should be reported and dealt with in a timely manner to avoid delaying treatment or causing irreversible damage.

Overall, pemetinib is a targeted drug that represents the direction of precision treatment. For specific patients with cholangiocarcinoma, its efficacy has been verified by multiple international studies. However, side effects cannot be ignored during treatment. Although most of them are controllable, they still need to be used with caution under the guidance of a doctor.

Reference materials:https://go.drugbank.com/drugs/DB15102